Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for Guided Therapeutics (GTHP) over the last 6 years, with Q3 2025 value amounting to $2000.0.

  • Guided Therapeutics' Depreciation and Depletion changed 0.0% to $2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $9000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $9000.0 for FY2024, which is 0.0% changed from last year.
  • Per Guided Therapeutics' latest filing, its Depreciation and Depletion stood at $2000.0 for Q3 2025, which was down 0.0% from $3000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Depreciation and Depletion ranged from a high of $2.3 million in Q3 2023 and a low of $1000.0 during Q3 2022
  • For the 4-year period, Guided Therapeutics' Depreciation and Depletion averaged around $180230.8, with its median value being $2000.0 (2023).
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 23150000.0% in 2023, then tumbled by 9991.36% in 2024.
  • Over the past 4 years, Guided Therapeutics' Depreciation and Depletion (Quarter) stood at $3000.0 in 2022, then crashed by 33.33% to $2000.0 in 2023, then changed by 0.0% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025.
  • Its Depreciation and Depletion was $2000.0 in Q3 2025, compared to $3000.0 in Q2 2025 and $2000.0 in Q1 2025.